Some tyrosine kinase inhibitors such as gilteritinib and sorafenib may penetrate the BBB and have shown promising results for the treatment of CNS leukemic involvement in FLT3-ITD AML.6,11,26. The gene discussed is FLT3; the disease is acute myeloid leukemia.